RxDoctor Payments Data

Thushan Desilva, MD

Dermatology · Boerne, TXNPI 1003824335

Payments from drug & device makers

$233,428in general payments, 2019–2025

Across 1,763 payments — averaging $132.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$131K
  • Galderma Laboratories, L.p.$25K
  • Regeneron Healthcare Solutions, Inc.$23K
  • UCB, Inc.$13K
  • Sanofi$8K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$5K
  • plus $28K from 43 others

What the payments were for

  • Consulting fees$24,12910%
  • Speaking & faculty fees$159,91269%
  • Travel & lodging$8,5974%
  • Food & beverage$39,95917%
  • Education$8310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,428 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$372,518
Medicare patients
1,104
Services billed
6,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast28$133,183
Dupixent PenDupilumab23$96,635
Metronidazole48$3,749
Tacrolimus13$3,210
Ketoconazole179$2,352
Fluorouracil40$2,317
Clobetasol Propionate41$1,254
Triamcinolone Acetonide60$708
Imiquimod22$577
Clindamycin Phosphate23$485
ValacyclovirValacyclovir Hcl18$358
Doxycycline Hyclate29$355
Mometasone Furoate17$335
Mupirocin34$259
Minoxidil15$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$859$133,18328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →